CEO: Paul Grayson.
Financial information: $38 million in venture capital to date, including a $25 million Series A round in 2009.
No. of local employees: 28.
Investors: 5AM Ventures, Apposite Capital LLP, Aravis SA, Merck Serono Ventures, SR One, and Versant Ventures.
Headquarters: Torrey Pines.
Year founded: 2007.
Company description: Anaphore is pursuing a new class of protein pharmaceuticals that target various cancers and autoimmune disorders, as well as other diseases.
Key factors for success: Anaphore is moving in a new direction with its treatment platform that promises to take biologics to a higher level in treating difficult to treat diseases.
The appointment of veteran life sciences executive Paul Grayson as the new president and CEO of Anaphore Inc...